SignalCorporate
IDEXX outlines 2026 revenue of $4.741B-$4.767B and EPS of $14.96-$15.16 as CoVet adds about $5M
IDEXX outlines 2026 revenue of $4.741B-$4.767B and EPS of $14.96-$15.16 as CoVet adds about $5M
Context
What happened: IDEXX Laboratories (IDXX) outlined 2026 revenue and EPS guidance on its Q3 2026 earnings call, with CoVet adding about $5M.
Key numbers: 2026 revenue guidance $4.741B to $4.767B. 2026 EPS guidance $14.96 to $15.16. CoVet contribution about $5M.
Why it matters: Management said third quarter results were driven by global execution, IDEXX innovations, and progress in increasing medically relevant use of diagnostics.
What changed
IDEXX Laboratories (IDXX) outlined 2026 revenue and EPS guidance on its Q3 2026 earnings call, with CoVet adding about $5M.
Why it matters
Management said third quarter results were driven by global execution, IDEXX innovations, and progress in increasing medically relevant use of diagnostics.